Alzheimer's disease (AD) is a multifactorial and heterogeneous disease with multiple contributors to its pathophysiology, including sleep disturbances, disorders, and circadian rhythm abnormalities. Mounting evidence supports the relationship between specific sleep features, circadian rhythm abnormalities, and AD pathophysiology (Ju et al., 2017; Olsson et al., 2018; Lucey et al., 2019; Minakawa et al., 2019; Winer et al., 2019; Mander, 2020; Wang and Holtzman, 2020). Recent studies have shown that the pathologic features of AD, including Aβ, tau, and neurodegeneration, all result in specific deficits in local and global sleep and circadian expression that depend on the underlying brain regions affected (Ju et al., 2017; Olsson et al., 2018; Lucey et al., 2019; Minakawa et al., 2019; Winer et al., 2019; Mander, 2020; Wang and Holtzman, 2020). More importantly, sleep disturbances and circadian rhythm abnormalities tend to co-occur with other AD modifiable risk factors (e.g., aging, vascular risk factors, mood, physical activity, diet, and lifestyle), some of which are associated with established biomarkers for AD progression (Elias et al., 2003; Luchsinger et al., 2005; Kaffashian et al., 2011; Gottesman et al., 2017). What remains unexamined are the combined effects of sleep disturbances/disorders, circadian rhythm abnormalities, and other commonly co-occurring modifiable risk factors on the biomarkers of AD pathology (Langbaum et al., 2012; Glodzik et al., 2014; Bangen et al., 2015; Gottesman et al., 2017; Vemuri et al., 2017). Further, methods to examine the confluence of these exposures have been limited, with potential causal mechanisms linking these synergistic exposures to AD progression yet to be fully understood. This Research Topic aimed to more deeply examine and understand the interactions between sleep, circadian rhythm abnormalities, and modifiable risk factors on both established and, more importantly, novel plasma AD markers, including markers of inflammation and axonal integrity.
In our first paper, Carvalho et al. examined whether sleepiness, as measured by the Epworth Sleepiness Scale (ESS), is associated with other biomarkers of Alzheimer's disease (AD), axonal integrity, and inflammation, which may also contribute to neurodegeneration and cognitive decline. This was a cross-sectional analysis of data from 260 cognitively unimpaired adults (>60 years) from the Mayo Clinic Study of Aging. Participants had CSF quantification of AD biomarkers (Aβ42, p-tau, p-tau/Aβ42) in addition to at least one of the following biomarkers: neurofilament light chain (NfL), interleukin-6 (IL-6), IL-10, or tumor necrosis factor-α (TNF-α). Adjusting was performed for age, sex, APOε4 status, body mass index, hypertension, dyslipidemia, and prior diagnosis of obstructive sleep apnea. Higher ESS scores were associated with higher CSF IL-6 and NfL but not with the other CSF biomarkers. A sensitivity analysis, however, showed that ESS scores were associated with CSF p-tau/Aβ42 in amyloid-positive participants. The findings suggest synergistic associations possibly exist between sleepiness and amyloid levels on p-tau/Aβ42, and this, in turn, may contribute to vulnerability to sleep disturbance, which may further amyloid accumulation in a feed-forward loop process. Recently, others and ourselves have shown that vascular risk factors and disturbed sleep, respectively, each act synergistically with the Aβ burden to promote cognitive decline (Rabin et al., 2018; Bubu et al., 2020, 2021, 2022). In addition, the Aβ burden and neuroimaging evidence of CVD pathology show additive effects on cognition (Marchant et al., 2012, 2013; Park et al., 2014; Vemuri et al., 2015; Kim et al., 2016).
Xiong et al. have provided a timely review on recent advances in our understanding of how sleep and circadian disorders can influence Alzheimer's disease pathology. Firstly, the authors covered basic science investigations of how sleep and circadian disturbance can alter two well-known pathological hallmarks of AD, amyloid beta and tau, as well as lesser-known contributions from oxidative stress, blood–brain barrier leakage, and brain region susceptibility to sleep fragmentation. Secondly, they highlighted the potential of both non-drug interventions of sleep and circadian disorders, such as bright light and physical exercise, and the effect of more common sleep drug interventions such as melatonin, benzodiazepines, and DORAs. Importantly, the review noted that substantial progress has been made in our understanding of the basic mechanisms that control the biological clock and the neural circuits involved in sleep. However, we know very little about how these systems are affected in the brain in neurodegenerative diseases, especially as it relates to other AD modifiable risk factors including sex, APOE4 status, depression, and drug use.
We are delighted to publish a report by Nick et al. who have added to our field the finding of an important neuronal susceptibility to chronic sleep fragmentation. In this paper, the authors examined the role of hypocretin/orexin (HCRT) in hippocampal and locus coeruleus neuronal injury in response to the chronic fragmentation of sleep in mice with and without HCRT. They show that with sleep fragmentation, the presence of HCRT increases amyloid beta and decreases cholinergic axon projections to the hippocampus, while not influencing sleep disruption effects on locus coeruleus neurons. Their report identifies a molecular mechanism in sleep loss-induced neural injury in the hippocampus and provides a rationale to assess the role of HCRT antagonists to prevent such sleep loss-induced hippocampal injury.
Our final paper in this topic by Turner et al. determined the interactive associations of apolipoprotein e4 (APOE-e4) and obstructive sleep apnea (OSA) on biomarkers of Alzheimer's disease and examined for the racial/ethnic differences of these associations. This study utilized baseline data from 1,387 participants (mean age = 69.73 ± 8.32; 58.6% female; 13.7% Black/African American, 18.4% of the sample had sleep apnea, and 37.9% were APOE-e4 carriers) in the National Alzheimer's Coordinating Center Uniform Dataset (NACC UDS). The biomarkers of AD that were assessed included CSF Aβ42, hippocampal volume, and white matter hyperintensities (WMH). A performance on the Montreal Cognitive Assessment (MOCA) was used as a surrogate for cognition. The findings show independent associations of OSA and APOE-e4 with CSF Aβ42, WMH volume, and MOCA scores. OSA and APOE-e4 did not interact to affect amyloid pathology; however, in Black/African American subjects, OSA and APOE-e4 interacted with significant associations with WMH and hippocampal volumes. These findings bolster the need for further research exploring the combined effects of modifiable and fixed risk factors for AD, especially in Black/African American populations, where this interaction may partially mediate increased levels of risk.
Overall, this special topic section presents the evidence of the associations between sleepiness and neuronal injury markers, with sleepiness and amyloid levels showing possible synergistic effects on p-tau/Aβ42. It also presents evidence—using WT mice models induced with chronic fragmentation—demonstrating that under conditions of sleep fragmentation, hypocretin/orexin is essential for the accumulation of amyloid-β. Moreover, it presents evidence showing that OSA and APOE-e4 are interactively associated with WHM in Black/African Americans. More importantly, the review highlights the need for more studies that provide a more comprehensive understanding of the mechanisms by which specific neurodegenerative diseases and pathogenic proteins affect the circadian rhythm and sleep system, as well as the interactions linking sleep and the circadian rhythm system with potential causal mechanisms resulting in synergistic exposure effects on AD progression. This topic remains an open and active area of research because of the continued need to understand both how and when to modify identifiable risk factors, not only across the general population but also with appropriate care and precision among minoritized populations who may suffer from a combination of under-characterization and under-appreciation in terms of AD risk.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
OB was supported by NIH/NIA/NHLBI (L30AG064670, K23AG068534, CIRAD P30AG059303 Pilot, NYU ADRC P30AG066512 Developmental Grant), Alzheimer's Association (AARG-D- 21-848397), BrightFocus Foundation (A2022033S), and American Academy of Sleep Medicine Foundation (AASM-BTS-231-BS-20). KK was supported by the American Academy of Sleep Medicine Foundation Focus Project Award and the Alzheimer's Association. AP was supported by NIH/NHLBI (K25HL151912 and R21HL165320). IA was supported by NIH/NHLBI/NIOSH (K24HL109156 and UO10HO11852).
Acknowledgments
We thank the authors who contributed to this topic.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Bangen K. J. Nation D. A. Delano-Wood L. Weissberger G. H. Hansen L. A. Galasko D. R. et al . (2015). Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement.11, 394–403.e391. 10.1016/j.jalz.2013.12.025
2
Bubu O. M. Kaur S. S. Mbah A. K. Umasabor-Bubu O. Q. Cejudo J. R. Debure L. et al . (2022). Obstructive sleep apnea and hypertension with longitudinal amyloid-β burden and cognitive changes. Am. J. Respir. Crit. Care Med.206, 632–636. 10.1164/rccm.202201-0107LE
3
Bubu O. M. Umasabor-Bubu O. Q. Turner A. D. Parekh A. Mullins A. E. Kam K. et al . (2020). Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression. Alzheimers Dement. 10.1002/alz.12184. [Epub ahead of print].
4
Bubu O. M. Williams E. T. Umasabor-Bubu O. Q. Kaur S. S. Turner A. D. Blanc J. et al . (2021). Interactive associations of neuropsychiatry inventory-questionnaire assessed sleep disturbance and vascular risk on Alzheimer's disease stage progression in clinically normal older adults. Front. Aging Neurosci.13, 763264. 10.3389/fnagi.2021.763264
5
Elias M. F. Elias P. K. Sullivan L. M. Wolf P. A. D'Agostino R. B. (2003). Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int. J. Obes. Relat. Metab. Disord.27, 260–268. 10.1038/sj.ijo.802225
6
Glodzik L. Rusinek H. Pirraglia E. McHugh P. Tsui W. Williams S. et al . (2014). Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. Neurobiol. Aging35, 64–71. 10.1016/j.neurobiolaging.2013.06.011
7
Gottesman R. F. Albert M. S. Alonso A. Coker L. H. Coresh J. Davis S. M. et al . (2017). Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort. JAMA Neurol.74, 1246–1254. 10.1001/jamaneurol.2017.1658
8
Ju Y. S. Ooms S. J. Sutphen C. Macauley S. L. Zangrilli M. A. Jerome G. et al . (2017). Slow wave sleep disruption increases cerebrospinal fluid amyloid-beta levels. Brain140, 2104–2111. 10.1093/brain/awx148
9
Kaffashian S. Dugravot A. Nabi H. Batty G. D. Brunner E. Kivimäki M. et al . (2011). Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Eur. Heart J.32, 2326–2332. 10.1093/eurheartj/ehr133
10
Kim H. J. Yang J. J. Kwon H. Kim C. Lee J. M. Chun P. et al . (2016). Relative impact of amyloid-beta, lacunes, and downstream imaging markers on cognitive trajectories. Brain 139 (Pt 9), 2516–2527. 10.1093/brain/aww148
11
Langbaum J. B. S. Chen K. Launer L. J. Fleisher A. S. Lee W. Liu X. et al . (2012). Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol. Aging33, 827.e811–829. 10.1016/j.neurobiolaging.2011.06.020
12
Lucey B. P. McCullough A. Landsness E. C. Toedebusch C. D. McLeland J. S. Zaza A. M. et al . (2019). Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. Sci. Transl. Med. 11, eaau6550. 10.1126/scitranslmed.aau6550
13
Luchsinger J. A. Reitz C. Honig L. S. Tang M. X. Shea S. Mayeux R. et al . (2005). Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology65, 545–551. 10.1212/01.wnl.0000172914.08967.dc
14
Mander B. A. (2020). Local sleep and Alzheimer's disease pathophysiology. Front. Neurosci.14, 525970. 10.3389/fnins.2020.525970
15
Marchant N. L. Reed B. R. DeCarli C. S. Madison C. M. Weiner M. W. Chui H. C. et al . (2012). Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiol. Aging33, 1006.e1025–1036. 10.1016/j.neurobiolaging.2011.10.001
16
Marchant N. L. Reed B. R. Sanossian N. Madison C. M. Kriger S. Dhada R. et al . (2013). The aging brain and cognition: contribution of vascular injury and abeta to mild cognitive dysfunction. JAMA Neurol.70, 488–495. 10.1001/2013.jamaneurol.405
17
Minakawa E. N. Wada K. Nagai Y. (2019). Sleep disturbance as a potential modifiable risk factor for Alzheimer's disease. Int. J. Mol. Sci.20, 803. 10.3390/ijms20040803
18
Olsson M. Arlig J. Hedner J. Blennow K. Zetterberg H. (2018). Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease. Sleep. 41, zsy025. 10.1093/sleep/zsy025
19
Park J.- H. Seo S. W. Kim C. Kim S. H. Kim G. H. Kim S. T. et al . (2014). Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol. Aging35, 254–260. 10.1016/j.neurobiolaging.2013.06.026
20
Rabin J. S. Schultz A. P. Hedden T. Viswanathan A. Marshall G. A. Kilpatrick E. et al . (2018). Interactive associations of vascular risk and beta-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the harvard aging brain study. JAMA Neurol.75, 1124–1131. 10.1001/jamaneurol.2018.1123
21
Vemuri P. Lesnick T. G. Przybelski S. A. Knopman D. S. Preboske G. M. Kantarci K. et al . (2015). Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain138(Pt 3), 761–771. 10.1093/brain/awu393
22
Vemuri P. Lesnick T. G. Przybelski S. A. Knopman D. S. Lowe V. J. Graff-Radford J. et al . (2017). Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Ann. Neurol.82, 706–718. 10.1002/ana.25071
23
Wang C. Holtzman D. M. (2020). Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology45, 104–120. 10.1038/s41386-019-0478-5
24
Winer J. R. Mander B. A. Helfrich R. F. Maass A. Harrison T. M. Baker S. L. et al . (2019). Sleep as a potential biomarker of Tau and β-amyloid burden in the human brain. J. Neurosci.39, 6315–6324. 10.1523/JNEUROSCI.0503-19.2019
Summary
Keywords
sleep disturbance, circadian rhythm disorders, Alzheimer's disease, biomarker, plasma
Citation
Bubu OM, Kam K, Parekh A and Ayappa I (2023) Editorial: Additive or synergistic impacts of sleep, circadian rhythm disturbances and other modifiable risk factors on established and novel plasma biomarkers of Alzheimer's disease pathology. Front. Aging Neurosci. 15:1168062. doi: 10.3389/fnagi.2023.1168062
Received
17 February 2023
Accepted
24 February 2023
Published
14 March 2023
Volume
15 - 2023
Edited and reviewed by
Agustin Ibanez, Latin American Brain Health Institute (BrainLat), Chile
Updates
Copyright
© 2023 Bubu, Kam, Parekh and Ayappa.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Omonigho M. Bubu omonigho.bubu@nyulangone.org
This article was submitted to Alzheimer's Disease and Related Dementias, a section of the journal Frontiers in Aging Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.